Dementia Drugmaker Axovant Draws $315M In Upsize IPO
Pharmaceutical company Axovant Sciences Ltd., which is developing a drug for the treatment of dementia in patients with Alzheimer's disease, raised $315 million with its initial public offering on Thursday, then...To view the full article, register now.
Already a subscriber? Click here to view full article